Molina Healthcare Q4 Earnings Miss Estimates on Growing Medical Costs

Molina Healthcare, Inc. MOH reported fourth-quarter 2024 adjusted earnings per share (EPS) of $5.05, which missed the Zacks Consensus Estimate of $5.81. However, the bottom line grew 15.3% from the year-ago period.Total revenues amounted to $10.5 billion, which improved 16% year over year. But the top line marginally missed the consensus mark.See the Zacks Earnings Calendar to stay ahead of market-making news.The weaker-than-expected fourth-quarter results included higher medical care costs, lower investment income and lower-than-expected membership growth. The negatives were partly offset by growing premiums, footprint and contract wins.MOH’s Full-Year 2024 FiguresMolina Healthcare’s total revenues of $40.65 billion increased from $34.07 billion a year ago and beat the estimate of $40.58 billion. Adjusted EPS grew from $20.88 per share to $22.65 in 2024 but missed the consensus mark of $23.44. Adjusted net income of $1.31 billion grew from $1.21 billion a year ago.Molina Healthcare, Inc Price, Consensus and EPS Surprise Molina Healthcare, Inc price-consensus-eps-surprise-chart | Molina Healthcare, Inc QuoteMOH’s Q4 Operational UpdatePremium revenues of $9.98 billion increased 19.4% year over year in the quarter under review and beat the Zacks Consensus Estimate of $9.85 billion and our estimate of $9.82 billion. The improvement stemmed from contract wins, buyouts and an expanding nationwide footprint, partly offset by Medicaid redeterminations.As of Dec. 31, 2024, total membership improved 10.8% year over year to around 5.5 million but missed the Zacks Consensus Estimate by 3.1%. The health insurer witnessed year-over-year increases in customers within its Medicaid, Medicare and Marketplace businesses.Investment income fell 2.6% year over year to $111 million but beat the consensus mark of $108.2 million.Total operating expenses of $10.1 billion increased 15.9% year over year and were higher than our model estimate of $9.7 billion due to a significant rise in medical care costs coupled with higher general and administrative expenses. Adjusted general and administrative expense ratio decreased to 6.3% in the fourth quarter from 7% a year ago. Interest expenses of $34 million rose from $27 million a year ago.The consolidated medical care ratio (medical costs as a percentage of premium revenues), or MCR, was 90.2% in the quarter under review. The metric rose from 89.1% a year ago and was higher than the consensus mark of 88.72%. Also, the figure was higher than our estimate of 88.6%.Molina Healthcare’s adjusted net income increased 12.2% year over year to $286 million.MOH’s Financial Update (as of Dec. 31, 2024)Molina Healthcare exited the fourth quarter with cash and cash equivalents of $4.66 billion, which declined from the 2023-end level of $4.85 billion. Total assets of $15.63 billion rose from $14.89 billion at 2023 end.Long-term debt of $2.92 billion rose from $2.18 billion at 2023-end.Total stockholders’ equity of $4.5 billion increased from the $4.2 billion figure at 2023-end.Net cash provided by operating activities amounted to $644 million in 2024 compared with $1.66 billion in 2023. The significant decline was due to differences in the timing of government receivables and payables.MOH’s 2025 GuidanceManagement expects premium revenues to be around $42 billion, which indicates an improvement of around 9% from the 2024 reported figure. Adjusted EPS is forecasted at a minimum of $24.50 this year, which implies a rise of roughly 8% from the 2024 figure. The company’s expanding legacy footprint and continued realization of new store-embedded earnings are likely to support growth.Adjusted net income is projected to be $1.36 billion, while GAAP net income is expected at $1.25 billion for 2025. Total membership is estimated to be 5.9 million by 2025-end. Consolidated MCR is likely to stay at 88.7%. It expects the effective tax rate to be 25.3% in 2025.Zacks Rank & Key PicksMolina Healthcare currently has a Zacks Rank #4 (Sell).Some better-ranked and promising stocks in the broader Medical sector are AnaptysBio, Inc. ANAB, LifeStance Health Group, Inc. LFST and Medpace Holdings, Inc. MEDP, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.The Zacks Consensus Estimate for AnaptysBio’s 2024 earnings remained stable over the past week. ANAB beat earnings estimates in two of the trailing four quarters and missed twice. The consensus mark for its 2024 revenues indicates 231.5% year-over-year growth.The Zacks Consensus Estimate for LifeStance’s 2024 earnings indicates a 64.7% year-over-year improvement. LFST beat earnings estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. The consensus mark for revenues implies 17.3% growth from the year-ago period.The Zacks Consensus Estimate for Medpace’s 2024 earnings implies a 34.4% increase from the year-ago reported figure. MEDP beat earnings estimates in each of the trailing four quarters, with an average surprise of 14.7%. The consensus mark for its current-year revenues is pegged at $2.1 billion, which indicates an 11.8% year-over-year increase.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Molina Healthcare, Inc (MOH): Free Stock Analysis Report Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report AnaptysBio, Inc. (ANAB): Free Stock Analysis Report LifeStance Health Group, Inc. (LFST): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks